Case Study Autoimmune Disease: In-Licensing

The business unit head of a major pharmaceutical company
hired L&C to:

  • Evaluate a potential in-licensing candidate for an autoimmune disease, based on phase II data:
    • assessment of whether this 2nd generation compound could be differentiated:
      • from 1st generation compounds of the same class
      • from three other compound classes
      • from all competitor compounds in the indication
Case Study Autoimmune Disease: In-Licensing


  • Data entry of > 130 clinical studies
  • Assessment of > 50 compounds in four classes across endpoints, side effects, and demographics
  • Analysis of features relevant to the study outcome: study design, compound features, and indication-specific parameters
  • > 200 different analyses performed (see one example on the left)


  • Identification of the most important factors impacting on study outcome and quantification of their relevance
  • Identification of the most comprehensive, objective, and quantitative rating for candidate licensing features: clear demonstration of superior efficacy across all compounds and compound classes and demonstration of comparable safety

Key Benefits

  • In-licensing decision regarding biomedical aspects mainly based on L&C analysis
  • Identification of key distinctive features for optimized product positioning